Kiadis names new CMO
This article was originally published in Scrip
Kiadis Pharma, a clinical-stage biopharmaceutical company developing T-cell immunotherapy treatments for blood cancers, has appointed Dr Jeroen Rovers chief medical officer. Most recently Dr Rovers was CMO at Ceronco Biosciences; though he was previously vice-president of medical affairs at Kiadis, and remained a consultant to the company until his re-appointment as CMO.
You may also be interested in...
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.
Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.